Precision Picks New CEO To Tackle Gene Editing’s Commercial Challenges

Michael Amoroso’s Yescarta Experience Valued

Precision is looking ahead to market access challenges for its off-the-shelf CAR-T and in vivo gene-editing therapies.

Precision Biosciences
• Source: Alamy

Precision BioSciences has appointed Michael Amoroso to be its new president and CEO, as the US biotech looks ahead to the regulatory and commercial challenges of bringing its off-the-shelf CAR-Ts and gene-editing therapies to market.

Amoroso is jumping ship to Precision just six months after being promoted to the role of CEO at another gene...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip